Component
Visceral adipose tissue area
Visceral adipose tissue area. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Berberine did not reduce visceral adipose area versus placebo; the between-group estimate was 1.4% with 97.5% CI -2.4% to 5.2%.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/berberine-research/41543854.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021", "start_char": 0, "end_char": 2354, "text_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021"}
- experimental_model
- Multicenter double-blind randomized placebo-controlled trial
- exposure
- Berberine 1 g/day for six months
- limitations
- No significant primary fat-reduction effect. Lipid endpoints were secondary; this population differs from diabetes trials and does not resolve every liver-disease subgroup.
- nutrient_topic
- Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine
- organism
- 337 diabetes-free adults with obesity and MASLD in China
- plain_language
- The trial did not show the expected visceral-fat benefit.
- primary_references
- [berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152
- tissue_or_cell_type
- CT visceral adipose area and liver fat; lipid endpoints
Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 1247–1258
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter double-blind randomized placebo-controlled trial · source_derived_draft · unverified_draft
### berberine-masld-visceral-null Berberine did not reduce visceral adipose area versus placebo; the between-group estimate was 1.4% with 97.5% CI -2.4% to 5.2%. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: The trial did not show the expected visceral-fat benefit. organism: 337 diabetes-free adults with obesity and MASLD in China tissue_or_cell_type: CT visceral adipose area and liver fat; lipid endpoints experimental_model: Multicenter double-blind randomized placebo-controlled trial limitations: No significant primary fat-reduction effect. Lipid endpoints were secondary; this population differs from diabetes trials and does not resolve every liver-disease subgroup. exposure: Berberine 1 g/day for six months evidence_span: {"source_cache": "artifacts/berberine-research/41543854.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021", "start_char": 0, "end_char": 2354, "text_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021"} [berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.